Source: International Congress 2018 – The immune response to tuberculosis: development of biomarkers and diagnostic tools
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Eremeeva (Yerfteriburg, Russian Federation), T. Tyulkova (Yerfteriburg, Russian Federation), L. Lavrechuk (Yerfteriburg, Russian Federation), K. Belousova (Yerfteriburg, Russian Federation), T. Umpeleva (Yerfteriburg, Russian Federation), D. Vakhrusheva (Yerfteriburg, Russian Federation). Features of development of TB infection caused by different doses of MBT. 4732

Member's Comments

No comment yet.

Related content which might interest you: Identification of high risk factors for development of active tuberculosis in children with latent tuberculosis infections Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017 Treatment of latent tuberculosis infection: completion rates and adverse effects Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease Source: Eur Respir J, 51 (1) 1701578; 10.1183/13993003.01578-2017 Year: 2018 The peculiarities of drug susceptibility of M. tuberculosis isolated from patients with late-stage HIV infection Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Different genetics background of patients with latent tuberculosis infection versus active tuberculosis Source: International Congress 2017 – Asthma genetics and genomics in patients and populations Year: 2017 Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2015; 46: 1397-1406 Year: 2015 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1594-1595 Year: 2016 Benefit of treatment of latent tuberculosis infection in individual patients Source: Eur Respir J 2016; 47:1592-1594 Year: 2016 Assessment of risk factors for the formation of polyorgan tuberculosis in children infected with MBT Source: Virtual Congress 2020 – Different aspects of paediatric viral and bacterial lung infections Year: 2020 Role of haptogobins genetically determined phenotypes in the development, treatment and prevention pulmonary tuberculosis Source: Annual Congress 2010 - Prognosis of tuberculosis Year: 2010 Completion of treatment for latent tuberculosis infection Source: Annual Congress 2011 - Clinical tuberculosis Year: 2011 Frequency of development acquired drug resistance in successful treated patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002 Latent tuberculosis infection in a drug treatment centre Source: Eur Respir J 2002; 20: Suppl. 38, 366s Year: 2002 Diagnosis and treatment of latent tuberculosis infection Source: Eur Respir Monogr 2018; 82: 381-398 Year: 2018 Non-cytokine activation immunoprofiling to differentiate treatment status in latent tuberculosis infection Source: Virtual Congress 2020 – Non-tuberculous mycobacteria and latent tuberculosis infection Year: 2020 Tuberculosis in children exposed to MTB with different drug resistance patterns Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Persistent M. tuberculosis infection: experimental model of endogenously re-activated TB Source: Eur Respir J 2002; 20: Suppl. 38, 582s Year: 2002 Interactive case presentation 2 : differentiation between active and latent TB infection Source: Annual Congress 2008 - PG20 - Advances in the diagnosis of Mycobacterium tuberculosis infection: an interactive, case-based course Year: 2008 Prevalence of CNS lesions in patients with pulmonary tuberculosis and HIV infection Source: International Congress 2019 – Tuberculosis: from diagnosis to complications Year: 2019